A pharmacokinetic standard for babies and adults.

The pharmacokinetic behavior of medicines used in humans follows largely predictable patterns across the human age range from premature babies to elderly adults. Most of the differences associated with age are in fact due to differences in size. Additional considerations are required to describe the processes of maturation of clearance processes and postnatal changes in body composition. Application of standard approaches to reporting pharmacokinetic parameters is essential for comparative human pharmacokinetic studies from babies to adults. A standardized comparison of pharmacokinetic parameters obtained in children and adults is shown for 46 drugs. Appropriate size scaling shows that children (over 2 years old) are similar to adults. Maturation changes are generally completed within the first 2 years of postnatal life; consequently babies may be considered as immature children, whereas children are just small adults.

[1]  H. Halliday,et al.  Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. , 2004, British journal of clinical pharmacology.

[2]  D. Tibboel,et al.  Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. , 2005, British journal of anaesthesia.

[3]  S. Gesase,et al.  Population Pharmacokinetic and Pharmacodynamic Properties of Intramuscular Quinine in Tanzanian Children with Severe Falciparum Malaria , 2012, Antimicrobial Agents and Chemotherapy.

[4]  P. Babyn,et al.  Changes in gastric emptying in early postnatal life. , 1997, The Journal of pediatrics.

[5]  D. Tibboel,et al.  Diclofenac pharmacokinetic meta‐analysis and dose recommendations for surgical pain in children aged 1–12 years , 2011, Paediatric anaesthesia.

[6]  D. Kaufman,et al.  Population Pharmacokinetics of Fluconazole in Young Infants , 2008, Antimicrobial Agents and Chemotherapy.

[7]  D. Tibboel,et al.  A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span , 2012, Pharmaceutical Research.

[8]  L. Wiesner,et al.  Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures , 2011, Paediatric anaesthesia.

[9]  S. Tibby,et al.  Extended-interval gentamicin: Population pharmacokinetics in pediatric critical illness , 2010, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[10]  N. Merchant,et al.  Pharmacokinetics of melatonin in preterm infants. , 2013, British journal of clinical pharmacology.

[11]  A W Kelman,et al.  Estimation of gentamicin clearance and volume of distribution in neonates and young children. , 1984, British journal of clinical pharmacology.

[12]  J. Bartlett,et al.  Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials , 1999, Antimicrobial Agents and Chemotherapy.

[13]  N. Holford,et al.  Prediction of morphine dose in humans , 2012, Paediatric anaesthesia.

[14]  G. Koren,et al.  Ontogeny of drug elimination by the human kidney , 2006, Pediatric Nephrology.

[15]  M O Karlsson,et al.  Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates. , 2007, British journal of clinical pharmacology.

[16]  P. Sánchez,et al.  Single-Dose Pharmacokinetics of Famciclovir in Infants and Population Pharmacokinetic Analysis in Infants and Children , 2010, Antimicrobial Agents and Chemotherapy.

[17]  J. McElnay,et al.  Population pharmacokinetics of single-dose intravenous paracetamol in children. , 2012, British journal of anaesthesia.

[18]  J. Lerman,et al.  Dexmedetomidine pharmacokinetics in pediatric intensive care – a pooled analysis , 2009, Paediatric anaesthesia.

[19]  James H. Brown,et al.  A General Model for the Origin of Allometric Scaling Laws in Biology , 1997, Science.

[20]  J. Clements,et al.  Pharmacokinetics and analgesic effect of ketamine in man. , 1981, British journal of anaesthesia.

[21]  J. Fourtillan,et al.  Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. , 2000, Biopharmaceutics & drug disposition.

[22]  S. Bell,et al.  Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients , 2006, Clinical pharmacokinetics.

[23]  M. Wiesen,et al.  Remifentanil Degradation in Umbilical Cord Blood of Preterm Infants , 2011, Anesthesiology.

[24]  G. Hempel,et al.  Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates , 2005, Antimicrobial Agents and Chemotherapy.

[25]  C. Coté,et al.  Uptake pharmacokinetics of the Fentanyl Oralet® in children scheduled for central venous access removal: implications for the timing of initiating painful procedures , 2002, Paediatric anaesthesia.

[26]  B. Anderson,et al.  The Pharmacokinetics of Ketorolac After Single Postoperative Intranasal Administration in Adolescent Patients , 2012, Anesthesia and analgesia.

[27]  M. Kuss,et al.  A Pharmacokinetic Study of Intramuscular (IM) Parecoxib Sodium in Normal Subjects , 2001, Journal of clinical pharmacology.

[28]  S. Urien,et al.  Developmental Pharmacokinetics of Lamivudine in 580 Pediatric Patients Ranging from Neonates to Adolescents , 2011, Antimicrobial Agents and Chemotherapy.

[29]  Nicholas H. G. Holford,et al.  A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.

[30]  Geoffrey B. West,et al.  The predominance of quarter-power scaling in biology , 2004 .

[31]  J. McElnay,et al.  Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study. , 2013, British journal of clinical pharmacology.

[32]  F. Suchy,et al.  Physiologic cholestasis: Elevation of the primary serum bile acid concentrations in normal infants , 1981 .

[33]  S. Schug,et al.  Recent Advances in the Pharmacokinetics of Local Anaesthetics , 1999, Clinical pharmacokinetics.

[34]  G. Warman,et al.  Clonidine disposition in children; a population analysis , 2007, Paediatric anaesthesia.

[35]  Hong-Guang Xie,et al.  Clonidine Clearance Matures Rapidly During the Early Postnatal Period: A Population Pharmacokinetic Analysis in Newborns With Neonatal Abstinence Syndrome , 2011, Journal of clinical pharmacology.

[36]  P. Krasilnikoff,et al.  Parietal cell secretory function in early childhood. , 1967, Scandinavian journal of gastroenterology.

[37]  C. Kirkpatrick,et al.  Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. , 2008, British journal of clinical pharmacology.

[38]  C. Kirkpatrick,et al.  The Relationship between Drug Clearance and Body Size , 2012, Clinical Pharmacokinetics.

[39]  N. Holford,et al.  Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. , 2004, British journal of clinical pharmacology.

[40]  Jennifer M Butler,et al.  Free Drug Metabolic Clearance in Elderly People , 2008, Clinical pharmacokinetics.

[41]  Stephanie Läer,et al.  Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. , 2008, British journal of clinical pharmacology.

[42]  J. L. Rosenberger,et al.  Transmucosal Administration of Midazolam for Premedication of Pediatric Patients: Comparison of the Nasal and Sublingual Routes , 1993, Anesthesiology.

[43]  C. Owen,et al.  BILE ACIDS IN INFANTS AND CHILDREN. , 1964, The Journal of laboratory and clinical medicine.

[44]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[45]  B. Walther,et al.  Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling , 2008, Fundamental & clinical pharmacology.

[46]  J. R. Sneyd,et al.  Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. , 2007, British journal of anaesthesia.

[47]  P. Siba,et al.  Pharmacokinetic Properties of Conventional and Double-Dose Sulfadoxine-Pyrimethamine Given as Intermittent Preventive Treatment in Infancy , 2011, Antimicrobial Agents and Chemotherapy.

[48]  N. Holford,et al.  Tips and traps analyzing pediatric PK data , 2011, Paediatric anaesthesia.

[49]  R. V. van Lingen,et al.  Acetaminophen Developmental Pharmacokinetics in Premature Neonates and Infants: A Pooled Population Analysis , 2002, Anesthesiology.

[50]  F. Torti,et al.  Development of the Human Gastrointestinal Tract: A Review , 1976 .

[51]  M. Gupta,et al.  Gastric retention in neonates. , 1978, Pediatrics.

[52]  M. Struys,et al.  Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. , 2010, British journal of anaesthesia.

[53]  U. Dubach,et al.  Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. , 1982, Bulletin of the World Health Organization.

[54]  K. Allegaert,et al.  Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability. , 2008, Drug Metabolism Letters.

[55]  K. Maitland,et al.  Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation , 2011, The Journal of antimicrobial chemotherapy.

[56]  U. Klotz,et al.  The effects of age and liver disease on the disposition and elimination of diazepam in adult man. , 1975, The Journal of clinical investigation.

[57]  Amin Rostami-Hodjegan,et al.  Changes in liver volume from birth to adulthood: A meta‐analysis , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[58]  V. Biran,et al.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings. , 2013, British journal of clinical pharmacology.

[59]  J. Gobburu,et al.  Population Pharmacokinetic–Based Dosing of Intravenous Busulfan in Pediatric Patients , 2007, Journal of clinical pharmacology.

[60]  V. Fellman,et al.  Thiopentone elimination in newborn infants: exploring Michaelis–Menten kinetics , 2011, Acta anaesthesiologica Scandinavica.

[61]  N H Holford,et al.  Target concentration intervention: beyond Y2K. , 2001, British journal of clinical pharmacology.

[62]  N. Holford,et al.  Mechanism-based concepts of size and maturity in pharmacokinetics. , 2008, Annual review of pharmacology and toxicology.

[63]  F. Lokiec,et al.  Pharmacokinetics of Oral Acyclovir in Neonates and in Infants: a Population Analysis , 2001, Antimicrobial Agents and Chemotherapy.

[64]  D. Mould,et al.  Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors , 2002, Clinical pharmacology and therapeutics.

[65]  N. Huang,et al.  Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. , 1953, The Journal of pediatrics.

[66]  N. Holford,et al.  Size, Myths and the Clinical Pharmacokinetics of Analgesia in Paediatric Patients , 1997, Clinical pharmacokinetics.

[67]  B. Anderson,et al.  A maturation model for midazolam clearance , 2011, Paediatric anaesthesia.

[68]  S. Higuchi,et al.  Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. , 2010, British journal of clinical pharmacology.

[69]  S. Salman,et al.  Development of a Population Pharmacokinetic Model for Parecoxib and Its Active Metabolite Valdecoxib after Parenteral Parecoxib Administration in Children , 2012, Anesthesiology.

[70]  H. Scheinin,et al.  Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. , 2003, British journal of clinical pharmacology.

[71]  N. Holford,et al.  Mechanistic basis of using body size and maturation to predict clearance in humans. , 2009, Drug metabolism and pharmacokinetics.

[72]  G. Glass,et al.  Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants , 1969, The American Journal of Digestive Diseases.

[73]  S. Urien,et al.  Population Pharmacokinetics of Tenofovir in HIV-1–Infected Pediatric Patients , 2011, Journal of acquired immune deficiency syndromes.

[74]  L. Aarons,et al.  Population pharmacokinetics and optimal design of paediatric studies for famciclovir. , 2009, British journal of clinical pharmacology.

[75]  N. Holford,et al.  Predicting weight using postmenstrual age – neonates to adults , 2011, Paediatric anaesthesia.

[76]  S. Khoo,et al.  Lopinavir/ritonavir population pharmacokinetics in neonates and infants. , 2011, British journal of clinical pharmacology.

[77]  W. Engle Age Terminology During the Perinatal Period , 2004, Pediatrics.

[78]  I. Murat,et al.  Maturational pharmacokinetics of single intravenous bolus of propofol , 2007, Paediatric anaesthesia.

[79]  M. Wiese,et al.  Predicted metabolic drug clearance with increasing adult age. , 2013, British journal of clinical pharmacology.

[80]  P. Moore Children are not small adults , 1998, The Lancet.

[81]  M. Coulthard,et al.  Human renal function maturation: a quantitative description using weight and postmenstrual age , 2009, Pediatric Nephrology.

[82]  R. Gristwood,et al.  Levobupivacaine: a new safer long acting local anaesthetic agent. , 1999, Expert opinion on investigational drugs.

[83]  N. Holford,et al.  Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. , 2007, British journal of clinical pharmacology.

[84]  D. Tibboel,et al.  From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II—Sensitivity to Physiological and Physicochemical Properties , 2012, CPT: pharmacometrics & systems pharmacology.

[85]  R. Jelliffe,et al.  Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. , 2002, The Journal of antimicrobial chemotherapy.

[86]  B. Friis‐Hansen Body water compartments in children: changes during growth and related changes in body composition. , 1961, Pediatrics.

[87]  G. Schwartz Does kL/PCr estimate GFR, or does GFR determine k? , 1992, Pediatric Nephrology.

[88]  A. Bensman,et al.  Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients , 2009, Clinical pharmacology and therapeutics.

[89]  R. Shellhaas,et al.  Population Pharmacokinetics of Phenobarbital in Infants With Neonatal Encephalopathy Treated With Therapeutic Hypothermia* , 2013, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[90]  J Schüttler,et al.  Population Pharmacokinetics of Propofol: A Multicenter Study , 2000, Anesthesiology.

[91]  J. Chen,et al.  Development of gastric slow waves in preterm infants measured by electrogastrography. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[92]  G. Chazot,et al.  Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection , 2004, European Journal of Clinical Pharmacology.

[93]  M. Gastonguay,et al.  Population Pharmacokinetic Modeling of Pantoprazole in Pediatric Patients From Birth to 16 Years , 2011, Journal of clinical pharmacology.

[94]  B. Anderson,et al.  Age and size are the major covariates for prediction of levobupivacaine clearance in children , 2006, Paediatric anaesthesia.

[95]  J. Barrett,et al.  Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months , 2009, European Journal of Clinical Pharmacology.